Background The recent introduction of magnetic resonance-guided radiation therapy
(MRgRT) has allowed improved treatment planning and delivery of stereotactic body …

Objective: Using moderate or ultra-hypofractionation, which is also known as stereotactic
body radiotherapy (SBRT) for treatment of localized prostate cancer patients has been …

Background Normofractionated radiation regimes for definitive prostate cancer treatment
usually extend over 7–8 weeks. Recently, moderate hypofractionation with doses per …

Background Stereotactic body radiotherapy (SBRT) is becoming increasingly used in
treating localized prostate cancer (PCa), with evidence showing similar toxicity and efficacy …

255 Background: Magnetic resonance imaging (MRI) guidance offers several theoretical
advantages over computed tomography (CT) guidance in the context of stereotactic body …

Purpose Use of stereotactic body radiation therapy (SBRT) is increasing in patients with
localized prostate cancer, but concerns about early and late gastrointestinal (GI) and …

Importance Magnetic resonance imaging (MRI) guidance offers multiple theoretical
advantages in the context of stereotactic body radiotherapy (SBRT) for prostate cancer …

Background Stereotactic body radiotherapy (SBRT) is gaining wider adoption for prostate
cancer management but there remain significant toxicity risks when delivering prostate …

Background Stereotactic body radiation therapy (SBRT) delivers high doses of radiation to
the prostate while minimizing radiation to adjacent normal tissues. Large fraction sizes may …

Background There is growing evidence that prostate cancer (PC) cells are more sensitive to
high fraction dose in hypofractionation schemes. High-dose-rate (HDR) brachytherapy as …